Albiruni Ryan Abdul Razak

TL;DR: In this paper , the authors evaluated hyper-progressive disease (HPD) in sarcoma patients treated in early-phase trials by assessing tumor growth rate (TGR) and describing their subsequent clinical outcomes.

TL;DR: Tegavivint is well tolerated with mostly Grade 1/2 adverse events and no Grade 3 TRAEs occurring in more than one patient, and the preliminary objective response rate of 18% in progressive desmoid tumors warrants continued research in the ongoing dose expansion portion of the study at the 5 mg/kg RP2D.

TL;DR: This paper showed that individuals with irAE have higher baseline IgG autoantibody (autoAb) levels with a greater increase in IgG and IgM autoAb after ICI administration, compared to those without irAE.

TL;DR: This study evaluates patient referral and enrollment patterns in a large academic phase I clinical trials program following the implementation of a molecular profiling program and found performance status and referral from a physician within the institution were associated with successful trial enrollment, whereas prior molecular profiling was not an independent predictor.

TL;DR: In this article , the impact of [18F]FDG PET/CT on the initial staging, restaging, clinical management, and outcomes of patients with soft-tissue and bone sarcomas was determined.